Literature DB >> 19944202

A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia.

Qing Geng1, Jacqueline Romero, Vikas Saini, Todd A Baker, Maria M Picken, Richard L Gamelli, Matthias Majetschak.   

Abstract

Molecular mechanisms leading to myocardial injury during warm or cold ischemia are insufficiently understood. Although proteasomes are thought to contribute to myocardial ischemia-reperfusion injury, their roles during the ischemic period remain elusive. Because donor hearts are commonly exposed to prolonged global cold ischemia prior to cardiac transplantation, we evaluated the role and regulation of the proteasome during cold ischemic storage of rat hearts in context of the myocardial ATP content. When measured at the actual tissue ATP concentration, cardiac proteasome peptidase activity increased by 225% as ATP declined during cold ischemic storage of hearts in University of Wisconsin (UW) solution for up to 48h. Addition of the specific proteasome inhibitor epoxomicin to the UW solution inhibited proteasome activity in the cardiac extracts, significantly reduced edema formation and preserved the ultrastructural integrity of the cardiomyocyte. Utilizing purified 20S/26S proteasome enzyme preparations, we demonstrate that this activation can be attributed to a subset of 26S proteasomes which are stable at ATP concentrations far below physiological levels, that ATP negatively regulates its activity and that maximal activation occurs at ATP concentrations in the low mumol/L range. These data suggest that proteasome activation is a pathophysiologically relevant mechanism of cold ischemic myocardial injury. A subset of 26S proteasomes appears to be a cell-destructive protease that is activated as ATP levels decline. Proteasome inhibition during cold ischemia preserves the ultrastructural integrity of the cardiomyocyte.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19944202      PMCID: PMC3904645          DOI: 10.1016/j.bbrc.2009.10.067

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

Review 1.  Getting activated with poly-ubiquitination.

Authors:  V Depraetere
Journal:  Nat Cell Biol       Date:  2001-08       Impact factor: 28.824

Review 2.  Proteasome inhibitors: from research tools to drug candidates.

Authors:  A F Kisselev; A L Goldberg
Journal:  Chem Biol       Date:  2001-08

3.  Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion.

Authors:  A L Bulteau; K C Lundberg; K M Humphries; H A Sadek; P A Szweda; B Friguet; L I Szweda
Journal:  J Biol Chem       Date:  2001-05-25       Impact factor: 5.157

4.  Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.

Authors:  Alexander Kloss; Silke Meiners; Antje Ludwig; Burkhardt Dahlmann
Journal:  Cardiovasc Res       Date:  2009-06-28       Impact factor: 10.787

5.  The dynamics of ubiquitin pools within cultured human lung fibroblasts.

Authors:  A L Haas; P M Bright
Journal:  J Biol Chem       Date:  1987-01-05       Impact factor: 5.157

6.  Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy.

Authors:  Meinrad Beer; Tobias Seyfarth; Jörn Sandstede; Wilfried Landschütz; Claudia Lipke; Herbert Köstler; Markus von Kienlin; Kerstin Harre; Dietbert Hahn; Stefan Neubauer
Journal:  J Am Coll Cardiol       Date:  2002-10-02       Impact factor: 24.094

7.  Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury.

Authors:  Joseph Pye; Farhad Ardeshirpour; Arlene McCain; Dwight A Bellinger; Elizabeth Merricks; Julian Adams; Peter J Elliott; Christine Pien; Thomas H Fischer; Albert S Baldwin; Timothy C Nichols
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11-07       Impact factor: 4.733

8.  Limitations of SLLVY-AMC in calpain and proteasome measurements.

Authors:  Christopher J Giguere; Rick G Schnellmann
Journal:  Biochem Biophys Res Commun       Date:  2008-05-05       Impact factor: 3.575

9.  Ubiquitin enhances the Th2 cytokine response and attenuates ischemia-reperfusion injury in the lung.

Authors:  Lisardo Garcia-Covarrubias; Eddie W Manning; Luis T Sorell; Si M Pham; Matthias Majetschak
Journal:  Crit Care Med       Date:  2008-03       Impact factor: 7.598

Review 10.  Recognition and processing of ubiquitin-protein conjugates by the proteasome.

Authors:  Daniel Finley
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

View more
  29 in total

1.  Dynamic imaging of autophagy-lysosomal pathway and autophagy function following pulmonary hypoxia/reoxygenation in vitro.

Authors:  Tian-Shu Liu; Yi-Ting Cai; Zhi-Fu Mao; Jie Huang; Tao Fan; Qing Geng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

2.  Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation.

Authors:  Todd A Baker; Qing Geng; Jacqueline Romero; Maria M Picken; Richard L Gamelli; Matthias Majetschak
Journal:  Biochem Biophys Res Commun       Date:  2010-09-26       Impact factor: 3.575

3.  Effects of the Kv7 voltage-activated potassium channel inhibitor linopirdine in rat models of haemorrhagic shock.

Authors:  Sean P Nassoiy; Favin S Babu; Heather M LaPorte; Kenneth L Byron; Matthias Majetschak
Journal:  Clin Exp Pharmacol Physiol       Date:  2018-04-27       Impact factor: 2.557

Review 4.  Emerging concepts in liver graft preservation.

Authors:  Mohamed Bejaoui; Eirini Pantazi; Emma Folch-Puy; Pedro M Baptista; Agustín García-Gil; René Adam; Joan Roselló-Catafau
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

5.  Effects of exogenous ubiquitin in a polytrauma model with blunt chest trauma.

Authors:  Todd A Baker; Jacqueline Romero; Harold H Bach; Joel A Strom; Richard L Gamelli; Matthias Majetschak
Journal:  Crit Care Med       Date:  2012-08       Impact factor: 7.598

6.  Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice.

Authors:  Zongwen Tian; Hanqiao Zheng; Jie Li; Yifan Li; Huabo Su; Xuejun Wang
Journal:  Circ Res       Date:  2012-06-26       Impact factor: 17.367

7.  Pharmacological modulation of C-X-C motif chemokine receptor 4 influences development of acute respiratory distress syndrome after lung ischaemia-reperfusion injury.

Authors:  Sean P Nassoiy; Favin S Babu; Heather M LaPorte; Matthias Majetschak
Journal:  Clin Exp Pharmacol Physiol       Date:  2017-09-20       Impact factor: 2.557

Review 8.  The ubiquitin proteasome system and myocardial ischemia.

Authors:  Justine Calise; Saul R Powell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-07       Impact factor: 4.733

9.  Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats.

Authors:  Harold H Bach; Heather M Laporte; Yee M Wong; Richard L Gamelli; Matthias Majetschak
Journal:  J Trauma Acute Care Surg       Date:  2013-02       Impact factor: 3.313

10.  Chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3 regulate vascular α₁-adrenergic receptor function.

Authors:  Harold H Bach; Yee M Wong; Abhishek Tripathi; Amanda M Nevins; Richard L Gamelli; Brian F Volkman; Kenneth L Byron; Matthias Majetschak
Journal:  Mol Med       Date:  2014-10-13       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.